Der eisenhaushalt bei der präoperativen eigenblutspende

Transfusion Medicine and Hemotherapy

Volumn 23, Issue 3, 1996, Pages 161-170

  Weisbach, V ^a   Eckstein, R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autologe Transfusion; Eigenblutspende; Eisen

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

BLOOD AUTOTRANSFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON METABOLISM; ORAL DRUG ADMINISTRATION; PREOPERATIVE PERIOD; REVIEW; BLEEDING; BLOOD; BLOOD VOLUME; DRUG EFFECT; ERYTHROPOIESIS; HOMEOSTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PREOPERATIVE CARE;

BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; BLOOD VOLUME; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HOMEOSTASIS; HUMANS; IRON; PREOPERATIVE CARE;

EID: 0029681793     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000223286     Document Type: Article

References (84)

1. BGH, Urteil v, 17, Dezember 1991 - VI ZR 40/91.
2. Eckstein R: Physiologische Aspekte der Eigenblutspende: in Mempel W, Heim MU (Hrsg.): Methoden der perioperativen Eigenbluttransfusion, Gräfelfing, Demeter, 1991, pp 39-42.
3. Eckstein R, Fellmer F, Emmlcr J, Zeiler T, Zimmermann R, Zingsem J, Heuft HG, Weisbach V: Eigenblutspende und Erythropoese, Beitr Infusionsther 1992;30:272-277.
4. Weisbach V, Zeiler T, Zingsem J, Holfeid-Özuysal C, Heuft HG, Eckstein R: Risiken der autologen Transfusion, Beitr Infusionsther 1991:28:310-312.
5. Dioodnough LT, Brittenham GM, Limitations of the erythropoietic response to serial phlebotomy: Implications for autologous blood donor programs, J Lab Clin Med 1990:115:28-35.
6. Weisbach V, Emmler J, Zeiler T, Zimmermann R, Zingsem J, Hardel M, Kirgis A, Fellmer F, Eckstein R: Hb-Verlauf orthopädischer Eigenblutpatienten, Beitr Infusionsther 1992:30:283-286.
7. Kickler TS, Spivak JL: Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors, JAMA 1988: 260:65-67.
8. Goodnough LI, Rudnick S, Price TH, Balias SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE, Silberstein LE, Smith KJ, Wallas CH, Abels R, von Tress M: Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy, N Engl J Med 1989:321:1163-1168.
9. Watanabe Y, Fuse K, Konishi T, Kobayasi T, Taka-zawa K, Konishi H, Shibata Y: Autologous blood transfusion with recombinant human erythropoietin in heart operations, Ann Thorac Surg 1991:51: 767-772.
10. Spivak JL: Recombinant human erythropoietin and its role in transfusion medicine (Editorial), Transfusion 1994:34:1-4.
11. Tasaki T, Ohio H, Hashimoto C, Abe R, Saitoh A, Kikuchi S: Recombinant human erythropoietin for autologous blood donation: Effects on perioperative red-blood-cell and serum erythropoietin production, Lancet 1992:339:773-775.
12. Graf H, Watzinger U, Ludvik B, Wagner A, Hocker P, Zweymuller KK: Recombinant human erythropoietin as adjuvant treatment for autologous blood donation, BMJ 1990;300:1627-1628.
13. Kvo S, Omoto R, Hirashima K, Eguchi S, Fujita T: Effect of human recombinant eryhlropoictin on reduction of homologous blood transfusion in open-hcart surgery, A Japanese Multicenter study, Circulation 1992;86:11413-418.
14. Watanabe Y, Fuse K, Naruse Y, Kobayashi T, Yamamoto S, Konishi H, Horii T, Shibata Y: Subcutaneous use of erythropoietin in heart surgery, Ann Thorac Surg 1992:54:483-484.
15. Mercuriali F, Zanella A, Barosi G, Inghilleri G, Biffi E, Vinci A, Colotti MT: Use of eryhlropoictin to increase the volume of autologous blood donated by orthopedic patients, Transfusion 1993:33:55-60.
16. Goodnough LT, Price TH, Rudnick S, Soegiarso RW: Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy, Transfusion 1992:32:441-445.
17. Biesma DH, Kraaijcmhagcn RJ, Marx JJM, van de Wiel A: The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy-induced anemia in autologous blood donors, Transfusion 1993:33:825-829.
18. Hayashi J, Shinonaga M, Nakalawa S, Miyamura H, Eguchi S, Shinada S: Does recombinant human erythropoietin accelerate erythropoiesis for predonation before cardiac surgery? Jpn Circ J 1993:57: 475-479.
19. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI: A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: Dose, response, toxicity, and efficacy, Transfusion 1994:34:66-71.
20. Weisbach V, Lauer G, Zingsem J, Neidhardt B, Zimmermann R, Weseloh G, Eckstein R: Intensivierte präoperative Eigenblutspende bei einem Patienten mit schwerer Hämophilie A und mehreren eryhtrozytären Alloantikörpern, Infusionsther Transfusionsmed 1994:21 (Supplement 2):64.
21. Ihompson FL, Powers JS, Gräber SH, Krantz SB: Use of recombinant human eryhtropoietin to enhance autologous blood donation in a patient with multiple red cell allo-antibodics and the anemia of chronic disease, Am J Med 1991:90:398-400.
22. Weisbach V, Zingsem J, Neidhardt B, Zeiler T, Eckstein R: Bedeutung der Eisenspeicher in der Eigenblutspende: in Mempel W, Heim MU, Schwarzfischer G, Mempel CH (Hrsg.): Eigenblultransfusion, Hämatologie, München, Sympomed, 1994, vol 3, pp 111-115.
23. Weisbach V, Zingsem J, Neidhardt B, Zimmermann R, Eckstein R: Anämisierung durch die präoperative Eigenblutspende - wie ist gegenzustcucm? in Mempel W, Schwarzfischer G, Mempel CH (Hrsg.): Eigenbluttransfusion heute, Hämatologie, München, Sympomed, 1995, vol 4, pp 28-33.
24. Coleman DH, Stevens AR, Dodge HT, Finch CA: Rate of blood regeneration after blood loss, Arch Intern Med 1953:341-349.
25. Finch S, Haskins D, Finch CA: Iron metabolism: Hcmatopoiesis following phlebotomy, Iron as a limiting factor, J Clin Invest 1950:29:1078-1086.
26. Eckstein R, Emmler J, Fellmer F, Zeiler T, Zimmer-mann R, Zingsem J, Heuft HG, Kirgis A, Weisbach V: Erythropoese und Eisenstoffwechsel bei der Eigenblutspende, Infusionstherapie 1992:19:56-58.
27. Goodnough LT, Price TH, Rudnick S: Iron-restricted eryhtropoiesis as a limitation to autologous blood donation in the erythropoietin-stimulated bone-marrow, J Lab Clin Med 1991:118:289-296.
28. Gordeuk VR, Brittenham GM, Hughes M, Keating L: High dose carbonyl iron for iron deficiency anemia: A randomized, double-blind trial, Am J Clin Nutr 1987:46:1029-1034.
29. Skikne B, Lynch S, Borek D, Cook J: Iron and blood donation, Clin Haematol 1984:13:271-287.
30. Kaltwasser JP: Eisenmangelanämien und Erkrankungen durch veränderten Eisenstoffwechsel: in Ostendorf PC (Hrsg.): Hämatologie, München, Urban und Schwarzenberg, 1991, pp 300-315.
31. Bothwell TH, Charlton RW, Cook JD, Finch CA: Iron metaholism in man, Oxford, Blackwell, 1979.
32. Fairbanks VF, Beutler E: Iron metabolism: in Williams WJ, Beutler E, Erslev AJ, Lichtman MA (eds): Hematology, New York, Mcgraw-Hill, 1990, vol 4, pp 329-339.
33. Promelli S: A micromethod for free eryhtrocytc porphyrins: The FEP lest, J Lab Clin Med 1973:81: 932-939.
34. Kaltwasser JP: Eisenstoffwechsel; in Mueller-Eckhardt C (Hrsg.): Transfusionsmedizin, Berlin, Springer, 1988, pp 101-122.
35. Lozoff B, Jimenez E, Wolf AW: Long-term developmental outcome of infants with iron deficiency, N Engl J Med 1991:325:687-694.
36. Oniara FO, Blakley BR: The effects of iron deficiency an iron overload on cell-mediated immunity in the mouse, Br J Nutr 1994;72:899-909.
37. Gordeuk VR, Brittenham GM, Bravo J, Hughes MA, Keating LJ: Prevention of iron deficiency with carbonyl iron in female blood donors, Transfusion 1990;30:239-245.
38. Ciordeuk VR, Brittenham GM, Hughes M A, Keating U: Carbonyl iron for short-term supplementation in female blood donors, Transfusion 1987:27:80-85.
39. Lieden G: Iron supplement to blood donors, I, Trials with intermittent iron supply, Acta Med Scand 1975:197:31-36.
40. Lieden G, Hoglund S, Ehn L: Iron supplement to blood donors, II, Effect of continuous iron supply, Acta Med Scand 1975;197:37-41.
41. Simon TL, Hunt WC, Garry PJ: Iron supplementation for menstruating female blood donors, Transfusion 1984;24:469-472.
42. Tobias KI, Camp FR, Linville D, Dedich SN, Parrish J, White WD: A laboratory report on iron supplementation in blood donors, Am J Forensic Med Pathol 1981;2:225-230.
43. Norrby A, Sölvell L: Iron absorption and haemoglobin regeneration in post-haemorrhagic anaemia-studies on the absorption pattern during oral iron therapy, Scand J Haematol 1974;20(suppl):75-106.
44. Mackintosh W, Jacobs P: Response in serum ferritin and haemoglobin to iron therapy in blood donors, Am J Hematol 1988;27:17-19.
45. Weisbach V, Emmler J, Fellmer F, Zeiler T, Zimmer-mann R, Zingsem J, Heuft HG, Kirgis A, Eckstein R: Eigenblutspende und Erythropoese, Münch Med Wocheischr 1993:135:48-50.
46. Biesma DH, Kraajenhagcn RJ, Poortmann J, Marx JJM, van de Wiel A: The effect of oral iron supplementation on eryhtropoiesis in autologous blood donors, Transfusion 1992:32:162-165.
47. Strauss RG: Iron for autologous blood donors needs more work (letter), Transfusion 1992;32:788-790.
48. Zauber NP, Zauber AG, Ciordon FJ, Tillis AC, Leeds HC, Berman E, Kudryk AB, Iron supplementation after femoral head replacement for patients with normal iron stores, JAMA 1992;267:525-527.
49. Kaltwasser JP, Hansen C, Oebike Y, Werner E: Assessment of iron availability using stable 54Fe, Eur J Clin Invest 1991;21:436-442.
50. Eckstein R, Weisbach V: Eigenblutentnahme und Eisenstoffwechsel; in Mempel W, Mempel M, Heim MU, Schwarzfischer G (Hrsg.): Eigenblultransfusion - eine aktuelle Übersicht; Hämatologie 2, München, Sympomed, 1992, pp 8-14.
51. Sachs V: Autologe Bluttransfusion; in Mueller-Eck-hardt (Hrsg.): Transfusionsmedizin, Berlin, Springer, 1988, pp 485-495.
52. Hallberg L, Ryttinger L, Sölvell L: Side-effects of oral iron therapy: A double-blind study of different iron compounds in tablet form, Acta Med Scand Suppl 1966;459:3-10.
53. Lichner S, Fleischer F, Meßmer K: Bietet die supportive intravenöse Eisendextrangabe bei der akuten präoperativen Eigenblutspende Vorteile? in Mempel W, Mempel M, Heim MU, Schwarzfischer G (Hrsg.): Eigenbluttransfusion eine aktuelle Übersicht: Hämatologie 2, München, Sympomcd, 1992; pp 179-184.
54. Kasper SM, Gcrlich W, Stark C, Börner U: Hämoglobingewinn bei der präoperativen Eigenblutspende mit und ohne supplementierende i.v, Eisenapplikation: in Mempel W, Schwarzfischer Ci, Mempel CH (Hrsg.): Eigenbluttransfusion heute, Hämatologie, München, Sympomed, 1995, vol 4, pp 172-175.
55. Schindler E, Scholz S, Boldt J, Zickmann B, Knothe Ch, Dietrich G, Hempelmann G: Wirkung oraler versus parenteraler Eisensubstitution bei Eigenblutspendern, Infusionsthcr Transfusionsmcd 1994; 21:236-241.
56. Woodman J, Shaw RJ, Shipman AJ, Edwards AM: A surveillance programme on a long-established product: Imferon (Iron Dextran BP), Pharm Med 1987:1:289-296.
57. Kaisi M, Ngwallc EWK, Runvoro DE, Rogers J: Evaluation of tolerance of and response to iron dex-tran (Imferon®) administered by total dose infusion to pregnant women with iron deficiency anemia, Ini J Gynecol Obstet 1988:26:235-243.
58. Kaltwasser JP: Gutachterliche Stellungnahme (Anmerkung der Autoren: zum Rote Hand Brief der Firma Rhöne-Poulenc Rorer zum Thema intravenöse Eisensubstitutionstherapie - Ferrlecit vom Dezember 1993), 1994.
59. Rhöne-Poulene Rorer: Intravenöse Eisensubstitutionstherapie - Ferrlecit, Rote Hand Brief, Dezember 1993.
60. Grimmel R: Persönliche Mitteilung, Firma Rhöne-Poulenc Rorer, 1993.
61. Von Bormann B, Aulich S: Autologe Transfusionsverfahren: Nutzen und Risiko, Dtsch Ärztebl 1993;90:2912-2918.
62. Von Bormann B, Weiler J, Aulich ST: Intravenöse Eisentherapie; in Mempel W, Heim MU, Schwarzfischer G, Mempel Ch (Hrsg.): Eigenbluttransfusion, Hämatologie, München, Sympomcd, 1994, vol 3, pp 109-110.
63. Geisser P, Baer M, Schaub E: Structure/histotoxicity relationship of parenteral iron preparations, Arzneimittelforschung/Drug Res 1992:42(11): 1439-1452.
64. Anatkov A, Gekova K: Hie use of large intravenous doses of iron in the treatment of iron-deficiency anaemia, Problems of hematology and blood transfusions in Medicine and Physioculture, 1970:13: 295-298(Übersetzung).
65. Chamate E: Treatment of iron deficiency anaemia in pregnancy and in immediate puerpurium and other ferropenic conditions, with saccharated iron administered intravenously in fractioned doses (Abstract), XIVV Int Congress of Haematology, 1972, Sao Paulo, Brazil.
66. Danielson BG: Supplementation with i.v, iron sucrose complex in patients with renal anaemia, Clinical Expert report, Uppsala, Sweden, Dec, 10., 1993.
67. Pascual J, Teruel JL, Liano F, Sureda A, Ortuno J: Intravenous Fe-gluconate-Na for iron-deficient patients on hemodialysis, Nephron 1992:60:121.
68. Sundcr-Plassmann G, Hörl WH: Iron metabolism and iron substitution during erythropoietin therapy, Clin Invest 1994;72:11-15.
69. Allegra V, Mengozzi G, Vasile A: Iron deficiency in maintenance hemodialysis patients: Assesment of diagnosis cirteria and of three different iron treatment, Nephron 1991;57:175-182.
70. Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJ: Anemia in rheumatoid arthritis: The role of iron, vitamin B 12 and folic acid deficiency, and erythropoietin responsiveness, Ann Rheum Dis 1990:49:93-98.
71. Cartwright GE: The anemia of chronic disorders, Semin Hematol 1966;3:351-375.
72. Samson D, Halliday D, Gumpel JM: Role of ineffective erythropoiesis in the anemia of rheumatoid arthritis, Ann Rheum Dis 1977;36:181-185.
73. Erslev AJ, Wilson J, Caro J: Erythropoietin titers in anemic, nonuremic patients, J Lab Clin Med 1987:109:429-433.
74. Takashina N, Kondo H, Kahiwazaka S: Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis, J Rheumatol 1990;17: 885-887.
75. Mercuriali F, Gualtieri CS, Sinigaglia L, Inghilleri G, Biffi F, Vinci A, Colotti MT, Barosi G, Lamber-tengh Deliliers G: Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery, Transfusion 1994:34: 501-506.
76. Means RT: Clinical application of recombinant erythropoietin in the anemia of chronic disease, Hematol Oncol Clin North Am 1994;8:933-944.
77. Miller CB, Joan RJ, Piantadosi S, Abeloff MD, Spivak JL: Decreased erythropoietin response in patients with the anemia of cancer, N Engl J Med 1990;332:1689-1692.
78. Henry' DH: Recombinant human erythropoietin in the treatment of the anemia associated with solid tumors; in Bauer C, Koch KM, Scigalla P, Wieczorek L (eds): Erythropoietin - Molecular Physiology and Clinical Applications, New York, Marcel Dekker, 1994, pp 293-298.
79. Ponchio L, Farina G, Pedrotti C, Rosti V, Bergamaschi G, Cazzola M: Recombinant human erythropoietin in hematological malignancies: in Bauer C Koch KM, Scigalla P, Wieczorek L (eds): Erythropoietin -Molecular Physiology and Clinical Applications, New York, Marcel Dekker, 1994, pp 311-320.
80. Richtlinien zur Blutgruppenbestimmung und Bluttransfusion, Aufgestellt vom wissenschaftlichen Beirat der Bundesärztekammer und vom Bundesgesundheitsamt, Köln, Deutscher Ärzte-Verlag, 1992, P 22.
81. Zauber NP, Zauber AG: Hematologic data of healthy very old people, JAMA 1987:257:2181-2184.
82. Lipschitz DA, Udupa KB, Milton KY, Uiompson CO: Effect of age on hematopoieses in man, Blood 1984:63:502-509.
83. Marx JJM: Normal iron absorption and decreased red cell iron uptake in the aged, Blood 1979:53: 204-211.
84. Tasaki T, Ohio H, Noguchi M, Motoki R, Kikuchi S, Sato A, Hoshino S: Iron and erythropoietin measurement in autologous blood donors with anemia: Implications for management, Transfusion 1994:34: 337-343.